stockrowCorcept Therapeutics Incorporated
CORT Healthcare Biotechnology
Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024.
- Revenue
- +64.0%
- EPS
- +525.8%
- Free cash flow
- +161.0%
Quarter to September 2026, against a year earlier
Follow CORT
Alert me
Corcept Therapeutics Incorporated (CORT) Return on equity
Corcept Therapeutics Incorporated's return on equity over the twelve months to 30 September 2026 was 21.7%, up 7.0 percentage points from fiscal 2025 (14.8%). Over the past ten years it has ranged from −84.8% (fiscal 2015) to 111.2% (fiscal 2017); the current reading is higher than 18% of that period. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 14.8% | (8.77) |
| FY2024 | 23.6% | 2.64 |
| FY2023 | 20.9% | (2.16) |
| FY2022 | 23.1% | (1.95) |
| FY2021 | 25.0% | 1.33 |
| FY2020 | 23.7% | (5.41) |
| FY2019 | 29.1% | (3.20) |
| FY2018 | 32.3% | (78.84) |
| FY2017 | 111.2% | 83.96 |
| FY2016 | 27.2% | 112.01 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| CYTK Cytokinetics, Incorporated compare | 184.7% |
| CORT Corcept Therapeutics Incorporated | 21.7% |
| KRYS Krystal Biotech, Inc. compare | 17.5% |
| PTGX Protagonist Therapeutics, Inc. compare | 11.0% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −24.8% |
| PRAX Praxis Precision Medicines, Inc. compare | −38.9% |
| SYRE Spyre Therapeutics, Inc. compare | −41.2% |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | −64.9% |
| ABVX Abivax SA Sponsored ADR compare | −249.8% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on CORT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement